Andrea Leith
Overview
Explore the profile of Andrea Leith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Artime E, Khare S, Zimner-Rapuch S, Redig J, Flannery C, Higgins V, et al.
SAGE Open Med
. 2025 Jan;
13:20503121241313082.
PMID: 39871849
Objectives: To explore the impact of obesity on clinical outcomes, health-related quality of life, emotional well-being, and work productivity in people/patients with obesity across six countries by body mass index...
2.
Lin Z, Si S, Liu J, Zhu H, Xu J, Artime E, et al.
Front Endocrinol (Lausanne)
. 2024 Nov;
15:1470394.
PMID: 39574954
Aims: To describe weight management and perceptions in China. Materials And Methods: Data were from the Adelphi Real World Obesity Disease Specific Programme™, a cross-sectional survey between April and July...
3.
Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy
Bugianesi E, Miele L, Donnarumma G, Grau K, Mancuso M, Prasad P, et al.
Pragmat Obs Res
. 2024 Oct;
15:185-200.
PMID: 39403308
Background: Although the estimated prevalence of non-alcoholic steatohepatitis (NASH) in Italy is 4-6%, little is known about patient characteristics and care pathways. Aim: To describe patient characteristics and management approaches...
4.
Barata P, Leith A, Ribbands A, Montgomery R, Last M, Arondekar B, et al.
Oncologist
. 2023 Apr;
28(9):e737-e747.
PMID: 37014097
Background: There is limited real-world evidence on how increasing use of treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC) has influenced treatment decisions in metastatic castration-resistant prostate cancer (mCRPC). The...
5.
Barata P, Leith A, Ribbands A, Montgomery R, Last M, Arondekar B, et al.
Oncologist
. 2023 Apr;
28(9):780-789.
PMID: 37014080
Background: Continuous androgen deprivation therapy ± first-generation non-steroidal antiandrogen was previously the standard-of-care for patients with metastatic castration-sensitive prostate cancer (mCSPC). Treatment intensification with novel hormonal therapy (NHT) or taxane...
6.
Leith A, Kiiskinen U, Girvan A, Jen M, Khela K, Rider A, et al.
Future Oncol
. 2022 Nov;
18(33):3727-3740.
PMID: 36377818
To investigate the association of discordance in patient- and physician-reported symptoms on health-related quality of life (HRQoL) in hepatocellular carcinoma (HCC). Data were drawn from a point-in-time survey of physicians...
7.
Leith A, Kim J, Ribbands A, Clayton E, Yang L, Ghate S
Adv Ther
. 2022 Mar;
39(5):2236-2255.
PMID: 35316501
Introduction: Prostate cancer (PC) is the second most common cancer, and the fifth most common cause of cancer-related mortality among male patients, worldwide. In Europe and Japan, the incidence of...
8.
Leith A, Ribbands A, Kim J, Clayton E, Gillespie-Akar L, Yang L, et al.
BMC Urol
. 2022 Mar;
22(1):33.
PMID: 35277153
Background: Until five years ago, the metastatic hormone-sensitive prostate cancer (mHSPC) treatment landscape was dominated by the use of androgen deprivation therapy (ADT) alone. However, novel hormonal agents (NHAs) and...
9.
Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, et al.
Future Oncol
. 2022 Jan;
18(8):937-951.
PMID: 35043687
To assess homologous recombination repair mutation (HRRm) testing patterns in metastatic castration-resistant prostate cancer. A point-in-time, international survey conducted January-August 2020. Three-quarters of physicians (oncologists, urologists, specialist surgeons) globally reported...
10.
Griffiths P, Peipert J, Leith A, Rider A, Morgan L, Cella D, et al.
Support Care Cancer
. 2022 Jan;
30(4):3613-3623.
PMID: 35031830
Purpose: With higher efficacy of cancer therapies, the numbers and types of side effects experienced by patients have also increased, evidencing a need for brief assessments of side effect bother....